This was the stock's second consecutive day of losses.

Last month, Regeneron had agreed to buy the firm for $256 million, beating an earlier $146 million bid from Wojcicki and the ...

The stock's fall snapped a two-day winning streak.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

GREENVILLE, S.C. (FOX Carolina/AP) - South Carolina is one of 27 states to join a lawsuit to block the sale of 23andMe users’ ...

Kenvue Inc.'s stock had its worst day in nearly two years on Tuesday, as the maker of Band-Aids, Benadryl and Tylenol said tariffs, persistent inflation and weaker demand for allergy medicine, due to ...

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease ...

Adam Turnquist, a technical strategist at LPL Financial, said the recovery in stock-market breadth is a particularly convincing bullish "tell" suggesting that the market's recovery appears to be on ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: CRISPR Therapeutics (NASDAQ: CRSP) and Regeneron Pharmaceuticals (NASDAQ: REGN).

This mixed outcome, combined with unmet high expectations for the drug’s performance, triggered a sharp sell-off ... looking for an AI stock that is more promising than REGN and that has ...

Wall Street analysts issued a fresh round of ratings changes on Friday, including notable downgrades for Airbnb (ABNB), Regeneron (REGN), and Cooper Companies (COO), and upgrades for Unity (U) and ...